– USA, PA / UK, Oxford – Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
“We are delighted that Barbara Duncan has agreed to join our Board of Directors,” commented Dr. Jonathan Knowles, Adaptimmune’s Chairman. “Her substantial financial and accounting expertise, combined with extensive experience in the life sciences sector, will augment well the skills and experience of our other Board members.”
“I am very pleased to join Adaptimmune at this exciting time in the Company’s development,” said Ms. Duncan. “I look forward to working with the team to support advancement of Adaptimmune’s clinical programs and help to progress the next growth stage of operations in the United Kingdom and USA.”
Barbara Duncan has over 15 years of experience in the life sciences industry. She has served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) since May 2009. Ms. Duncan currently serves as a director for public company, Medgenics, Inc. (NYSE:MDGN) and for privately held Edgemont Pharmaceuticals, LLC. She previously served as Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceuticals, Inc. from 2001 to 2009. Before that, she served as Vice President of Corporate Finance – Global Healthcare at Lehman Brothers Inc. and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University.
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.